Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO

The video discusses market concerns and outlines 2018 as a transition year with investments in future growth. It explains the reasons for profit decline, mainly due to currency effects and investments in healthcare. The liquid crystals market is expected to decline but stabilize by 2020. M&A activities are limited due to a focus on deleveraging. The life sciences unit shows strong growth driven by research, process solutions, and applied segments.

What is the primary reason for the decline in operating profit?

• Increased competition

• Negative currency effects

• Decreased demand

• Higher taxes

What is the expected growth rate for the liquid crystals business after 2019?

• 4-5%

• 3-4%

• 1-2%

• 2-3%

What is the company's strategy to maintain market share in liquid crystals?

• Lowering prices

• Increasing advertising

• Quality leadership and reliability

• Expanding into new markets

What is the company's focus regarding mergers and acquisitions?

• Merging with competitors

• Entering new industries

• Deleveraging and small acquisitions

• Expanding rapidly

What will the net cash proceeds from the sale of the consumer health business be used for?

• Research and development

• Deleveraging

• Marketing campaigns

• Employee bonuses

Which segment is NOT mentioned as a driver for growth in the life sciences unit?

• Applied segment

• Process solutions

• Research solutions

• Consumer electronics

What trend is contributing to growth in the applied segment of life sciences?

• Decreasing population

• Rising quality standards

• Lower testing needs

• Reduced regulations